Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02681094 · ClinicalTrials.gov registry record · Phase 3
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 905
- Enrollment target
NCT02681094 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 905 participants.
The verdict
NCT02681094, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 905 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate safety and efficacy of therapy with saxagliptin 5mg co-administered with dapagliflozin 5mg, compared to therapy with saxagliptin 5mg or dapagliflozin 5mg in patients who are inadequately controlled on ≥1500mg/day of metformin monotherapy.
Interventions
- DRUG Dapagliflozin
- DRUG Saxagliptin
- DRUG Placebo for Dapagliflozin
- DRUG Placebo for Saxagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 905 participants |
| Start Date | 2016-02-26 |
| Est. Completion | 2017-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02681094
The ClinicalTrials.gov registry entry for NCT02681094 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 905 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dapagliflozin is the first listed.
NCT02681094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02681094 about?
NCT02681094 is a clinical study titled "A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes". The aim of this study is to evaluate safety and efficacy of therapy with saxagliptin 5mg co-administered with dapagliflozin 5mg, compared to therapy with saxagliptin 5mg or dapagliflozin 5mg in patients who are inadequately controlled on ≥1500mg/day of metformin monotherapy.
What is the current status of trial NCT02681094?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 905 participants. The study started on 2016-02-26. Estimated completion is 2017-07-15.
What interventions are being tested in trial NCT02681094?
The interventions under investigation include: Dapagliflozin (DRUG), Saxagliptin (DRUG), Placebo for Dapagliflozin (DRUG), Placebo for Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT02681094?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.